Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Eli Lilly experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant year-over-year ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...
Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...
Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy ... president of Lilly Cardiometabolic Health and Lilly USA. "Our goal is to break down barriers and provide ...
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will prevent heart attacks and strokes. By Gina Kolata As many as one in five ...
Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership ...
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has ... according to media reports. At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback